

Andrea Silber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3994842/publications.pdf>

Version: 2024-02-01

20
papers

229
citations

1040056

9
h-index

1199594

12
g-index

21
all docs

21
docs citations

21
times ranked

463
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2587-2597.	7.0	16
2	Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 516-516.	1.6	0
3	Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12007-12007.	1.6	0
4	Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 9.	5.2	35
5	Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2021, 109, 106508.	1.8	8
6	The impact of communication style on patient satisfaction. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 349-356.	2.5	16
7	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. <i>Journal of Clinical Oncology</i> , 2019, 37, 1365-1369.	1.6	17
8	Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 247-259.	2.5	43
9	Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 333-340.	2.5	16
10	Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?. <i>American Journal of Surgery</i> , 2017, 214, 1082-1088.	1.8	29
11	Discussion of: "Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?". <i>American Journal of Surgery</i> , 2017, 214, 1089-1090.	1.8	0
12	Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. <i>Journal of Oncology Practice</i> , 2017, 13, e1012-e1020.	2.5	6
13	Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. <i>Oncotarget</i> , 2016, 7, 22064-22076.	1.8	10
14	Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18136-e18136.	1.6	0
15	Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 533-541.	2.5	31
16	Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 538-538.	1.6	0
17	Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12564-e12564.	1.6	0
18	Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11501-e11501.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.. Journal of Clinical Oncology, 2014, 32, 2561-2561.	1.6	0
20	Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (<scp>Tâ€œDM1</scp>). British Journal of Dermatology, 0, , .	1.5	0